by Alison Bass | Nov 26, 2012 | biotech industry, drug marketing, medical devices, opiods, pharmaceutical industry, prescription drug abuse, public health, Uncategorized
In my previous blogs about West Virginia’s shockingly high rate of prescription drug overdoses — the Mountain State has the second highest rate of overdoses in the nation — I focused on “the culture of disability” that created this...
by Alison Bass | Jun 7, 2012 | biotech industry, clinical trials, conflicts of interest, pharmaceutical industry, Uncategorized
Senator Charles Grassley is upping the ante on the controversy surrounding the Vertex pharmaceutical executives who cashed in on overstated clinical trial data — see my blog from last week. According to The Boston Globe, which broke the Vertex story, Grassley...
by Alison Bass | May 30, 2012 | biotech industry, clinical trials, conflicts of interest, drug marketing, pharmaceutical industry, Uncategorized
Senior executives at Vertex Pharmaceuticals made millions of dollars each by selling company stock in the days after the Cambridge-based pharmaceutical reported promising clinical trial data on an experimental drug for cystic fibrosis. And then weeks after they cashed...
by Alison Bass | Apr 27, 2012 | antidepressants, biotech industry, clinical trials, continuing medical education, drug marketing, FDA, health care costs, medical devices, patient care, pharmaceutical industry, scientific misconduct, suicide rates, Uncategorized
Is the Food and Drug Administration violating its own mandate to approve safe drugs? That was the question that Donald Light, co-author of The Risk for Prescription Drugs and a long-time medical sociologist, posed at a talk yesterday at Brandeis University. The...
by Alison Bass | Nov 17, 2011 | biotech industry, clinical trials, conflicts of interest, patient care, pharmaceutical industry, Uncategorized, university industry collaboration
We’ve all signed those vague privacy statements when visiting our local hospital for medical care. But how many of us have actually read the fine print and understand that the most sensitive details of our medical lives may be shared with drug companies for...
by Alison Bass | Jun 27, 2011 | biotech industry, conflicts of interest, drug marketing, health care costs, medical devices, pharmaceutical industry
A page-one story in The Boston Globe today spotlights the Massachusetts biotech industry’s effort to block a key piece of President Obama’s health care overhaul: the creation of an independent payment advisory board (IPAB) that would make recommendations...